登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Integrin alpha V beta 6】

Integrin alpha V beta 6信息

英文名称:Integrin alpha-V/beta-6
中文名称:整合素α-V/β-6复合体
靶点别称
上市药物数量:0
临床药物数量:4
最高研发阶段:临床二期

Integrin alpha V beta 6产品列表

ACRO质量管理体系
 
评论(1)
IT6-H82E4|Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
  1. 475XXXXXXX
  2. 2人赞
  3. Great communication from the Acro team--quickly received an email detailing the estimated delivery timeframe and asking if that timeframe was acceptable. Product was ready per the timeline provided by the Acro biosystems team and shipped. This was a new product for us (though we’ve used other acro biosystems products previously) and worked well for our intended use with Surface Plasmon Resonance (SPR). Thank you all!
  4. 2022-04-02
 

Integrin alpha V beta 6分子别名

Integrin alpha V beta 6,ITGAV&ITGB6

Integrin alpha V beta 6分子背景

Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.

Integrin alpha V beta 6临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
OTT-166 OTT-166 临床二期 OcuTerra Therapeutics Inc 糖尿病视网膜病变 详情
[18F]FP-R01-MG [18F]FP-R01-MG; [18F]FP-R01-MG-F2 临床一期 Pliant Therapeutics Inc, 斯坦福大学, 中国医学科学院北京协和医学院 特发性肺纤维化, 新型冠状病毒感染, 胰腺癌, 原发性硬化性胆管炎, 脑转移, 肺癌, 非小细胞肺癌 详情
IDL-2965 IDL-2965 临床二期 Indalo Therapeutics Inc 非酒精性脂肪肝, 特发性肺纤维化 详情
PLN-74809 PLN-74809 临床二期 Pliant Therapeutics Inc 特发性肺纤维化, 新型冠状病毒感染, 成人呼吸窘迫综合征, 原发性硬化性胆管炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定